Pharma

Your Article Summary

See Latest Articles

Update on FDA Registration of Actemra, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody for Rheumatoid Arthritis
Chugai Pharmaceutical Co., 09/02/09

Chugai Pharmaceutical Co., Ltd. and F. Hoffmann–La Roche Ltd.announced that FDA has accepted the complete response resubmission that Roche made to the U.S. Food and Drug Administration for the Biologics License Application for Actemra®the humanized anti–human IL–6 receptor monoclonal antibody, following the receipt of the Complete Response Letter in September 2008.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 2010
Cell Therapeutics, 12/18/09

Eslicarbazepine: A novel antiepileptic agent designed for improved efficacy and safety
Formulary , 12/16/09

Human genome sciences announces submission of marketing authorization application to emea for joulferon
Human Genome Sciences, 12/16/09

 See all of Drug/Product Approvals